{"name":"BioNTech SE","slug":"biontech","ticker":"BNTX","exchange":"NASDAQ","domain":"biontech.com","description":"BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.","hq":"Mainz, Germany","founded":2008,"employees":"7807","ceo":"Ugur Sahin","sector":"Biotech","stockPrice":91.34,"stockChange":1.72,"stockChangePercent":1.92,"marketCap":"$23.1B","metrics":{"revenue":4000000000,"revenueGrowth":-23.7,"grossMargin":78.7,"rdSpend":0,"netIncome":-1136099968,"cash":13740600320,"dividendYield":0,"peRatio":-21.6,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Ritonavir patent cliff ($1.2B at risk)","drug":"Ritonavir","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"oncology","drugs":[{"name":"Influenza","genericName":"Influenza and COVID-19 Combination A","slug":"influenza-and-covid-19-combination-a","indication":"Symptoms of colds and flu","status":"marketed"},{"name":"Influenza","genericName":"Influenza and COVID-19 Combination B","slug":"influenza-and-covid-19-combination-b","indication":"aches","status":"marketed"},{"name":"Investigational Influenza Vaccine","genericName":"Investigational Influenza Vaccine","slug":"investigational-influenza-vaccine","indication":"Other","status":"phase_3"},{"name":"Licensed COVID-19 Vaccine","genericName":"Licensed COVID-19 Vaccine","slug":"licensed-covid-19-vaccine","indication":"Other","status":"phase_1"},{"name":"Licensed Influenza Vaccine 1","genericName":"Licensed Influenza Vaccine 1","slug":"licensed-influenza-vaccine-1","indication":"Other","status":"phase_1"},{"name":"Licensed Influenza Vaccine 2","genericName":"Licensed Influenza Vaccine 2","slug":"licensed-influenza-vaccine-2","indication":"Influenza prevention","status":"marketed"},{"name":"BNT152","genericName":"BNT152","slug":"bnt152","indication":"Other","status":"phase_1"},{"name":"BNT162b2SA","genericName":"BNT162b2SA","slug":"bnt162b2sa","indication":"Other","status":"phase_2"},{"name":"BNT162b2s01","genericName":"BNT162b2s01","slug":"bnt162b2s01","indication":"Other","status":"phase_2"},{"name":"Pumitamig","genericName":"Pumitamig","slug":"pumitamig","indication":"Other","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"cardiovascular","drugs":[{"name":"Investigational COVID-19 Vaccine","genericName":"Investigational COVID-19 Vaccine","slug":"investigational-covid-19-vaccine","indication":"Prevention of COVID-19 in individuals 5 years of age and older","status":"marketed"},{"name":"BNT111","genericName":"BNT111","slug":"bnt111","indication":"COVID-19 prevention","status":"phase_2"},{"name":"BNT162b1","genericName":"BNT162b1","slug":"bnt162b1","indication":"COVID-19 prevention","status":"phase_2"},{"name":"BNT162b2.B.1.351","genericName":"BNT162b2.B.1.351","slug":"bnt162b2-b-1-351","indication":"COVID-19 prevention (variant-specific booster or primary series against B.1.351 variant)","status":"phase_3"},{"name":"BNT324","genericName":"BNT324","slug":"bnt324","indication":"Prevention of respiratory syncytial virus (RSV) infection in adults aged 60 years and older","status":"phase_3"},{"name":"BNT327 Equivalent Q3W Dose","genericName":"BNT327 Equivalent Q3W Dose","slug":"bnt327-equivalent-q3w-dose","indication":"COVID-19 prevention","status":"phase_2"},{"name":"BNT327 Optimized Dose","genericName":"BNT327 Optimized Dose","slug":"bnt327-optimized-dose","indication":"Prevention of COVID-19","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"neuroscience","drugs":[{"name":"BNT166a","genericName":"BNT166a","slug":"bnt166a","indication":"Melanoma (in combination with Merck's Keytruda/pembrolizumab)","status":"phase_2"},{"name":"BNT323/DB-1303","genericName":"BNT323/DB-1303","slug":"bnt323-db-1303","indication":"Solid tumors (specific indication under clinical evaluation in Phase 3)","status":"phase_3"},{"name":"Nab-paclitaxel/Paclitaxel","genericName":"Nab-paclitaxel/Paclitaxel","slug":"nab-paclitaxel-paclitaxel","indication":"Metastatic breast cancer","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Assorted Licensed Hand Sanitizer Grape 01","genericName":"Licensed Influenza Vaccine 3","slug":"licensed-influenza-vaccine-3","indication":"Intranasal influenza vaccine for active immunization against influenza disease caused by influenza virus types A and B, in individuals 6 years of age and older","status":"marketed"}]}],"pipeline":[{"name":"Influenza","genericName":"Influenza and COVID-19 Combination A","slug":"influenza-and-covid-19-combination-a","phase":"marketed","mechanism":"SARS-CoV-2 spike protein and influenza hemagglutinin protein","indications":["Symptoms of colds and flu"],"catalyst":""},{"name":"Assorted Licensed Hand Sanitizer Grape 01","genericName":"Licensed Influenza Vaccine 3","slug":"licensed-influenza-vaccine-3","phase":"marketed","mechanism":"Influenza virus hemagglutinin protein","indications":["Intranasal influenza vaccine for active immunization against influenza disease caused by influenza virus types A and B, in individuals 6 years of age and older"],"catalyst":""},{"name":"Influenza","genericName":"Influenza and COVID-19 Combination B","slug":"influenza-and-covid-19-combination-b","phase":"marketed","mechanism":"Not specified","indications":["aches","cold symptoms","cramping","discomfort","fatigue"],"catalyst":""},{"name":"Investigational COVID-19 Vaccine","genericName":"Investigational COVID-19 Vaccine","slug":"investigational-covid-19-vaccine","phase":"marketed","mechanism":"Not specified","indications":["Prevention of COVID-19 in individuals 5 years of age and older","Prevention of COVID-19 in individuals 6 months through 4 years of age","Prevention of COVID-19 in individuals 12 years of age and older","Prevention of COVID-19 in individuals 6 months through 4 years of age with certain health conditions","Prevention of COVID-19 in individuals 5 years of age and older with certain health conditions"],"catalyst":""},{"name":"Investigational Influenza Vaccine","genericName":"Investigational Influenza Vaccine","slug":"investigational-influenza-vaccine","phase":"phase_3","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Licensed COVID-19 Vaccine","genericName":"Licensed COVID-19 Vaccine","slug":"licensed-covid-19-vaccine","phase":"phase_1","mechanism":"The vaccine uses mRNA to instruct cells to produce a harmless piece of the spike protein, triggering an immune response.","indications":[],"catalyst":""},{"name":"Licensed Influenza Vaccine 1","genericName":"Licensed Influenza Vaccine 1","slug":"licensed-influenza-vaccine-1","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Licensed Influenza Vaccine 2","genericName":"Licensed Influenza Vaccine 2","slug":"licensed-influenza-vaccine-2","phase":"marketed","mechanism":"Not specified","indications":["Influenza prevention","Influenza protection","Influenza prevention for adults and children 6 years and older"],"catalyst":""},{"name":"BNT152","genericName":"BNT152","slug":"bnt152","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BNT166a","genericName":"BNT166a","slug":"bnt166a","phase":"phase_2","mechanism":"BNT166a is an mRNA vaccine designed to encode tumor-associated antigens and stimulate anti-tumor immune responses.","indications":["Melanoma (in combination with Merck's Keytruda/pembrolizumab)","Colorectal cancer (in development)"],"catalyst":""},{"name":"BNT111","genericName":"BNT111","slug":"bnt111","phase":"phase_2","mechanism":"BNT111 is a COVID-19 vaccine candidate.","indications":["COVID-19 prevention"],"catalyst":""},{"name":"BNT162b1","genericName":"BNT162b1","slug":"bnt162b1","phase":"phase_2","mechanism":"mRNA-based vaccine","indications":["COVID-19 prevention"],"catalyst":""},{"name":"BNT162b2.B.1.351","genericName":"BNT162b2.B.1.351","slug":"bnt162b2-b-1-351","phase":"phase_3","mechanism":"BNT162b2.B.1.351 is an mRNA vaccine encoding a modified spike protein from the B.1.351 (Beta) variant of SARS-CoV-2, designed to elicit immune responses against this variant.","indications":["COVID-19 prevention (variant-specific booster or primary series against B.1.351 variant)"],"catalyst":""},{"name":"BNT162b2SA","genericName":"BNT162b2SA","slug":"bnt162b2sa","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"BNT162b2s01","genericName":"BNT162b2s01","slug":"bnt162b2s01","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"BNT323/DB-1303","genericName":"BNT323/DB-1303","slug":"bnt323-db-1303","phase":"phase_3","mechanism":"BNT323/DB-1303 is a bispecific antibody that simultaneously engages tumor-associated antigens and immune effector cells to redirect immune responses against cancer cells.","indications":["Solid tumors (specific indication under clinical evaluation in Phase 3)"],"catalyst":""},{"name":"BNT324","genericName":"BNT324","slug":"bnt324","phase":"phase_3","mechanism":"BNT324 is an mRNA vaccine designed to elicit an immune response against RSV (respiratory syncytial virus) by encoding viral antigens.","indications":["Prevention of respiratory syncytial virus (RSV) infection in adults aged 60 years and older","Prevention of RSV disease in older adults"],"catalyst":""},{"name":"BNT327 Equivalent Q3W Dose","genericName":"BNT327 Equivalent Q3W Dose","slug":"bnt327-equivalent-q3w-dose","phase":"phase_2","mechanism":"BNT327 is a COVID-19 vaccine candidate that uses a modified mRNA molecule to instruct cells to produce a piece of the SARS-CoQV-2 virus, eliciting an immune response.","indications":["COVID-19 prevention"],"catalyst":""},{"name":"BNT327 Optimized Dose","genericName":"BNT327 Optimized Dose","slug":"bnt327-optimized-dose","phase":"phase_2","mechanism":"BNT327 is a mRNA-based vaccine that encodes for the SARS-CoV-2 spike protein.","indications":["Prevention of COVID-19"],"catalyst":""},{"name":"Nab-paclitaxel/Paclitaxel","genericName":"Nab-paclitaxel/Paclitaxel","slug":"nab-paclitaxel-paclitaxel","phase":"phase_3","mechanism":"Nab-paclitaxel is an albumin-bound formulation of paclitaxel that stabilizes microtubules to prevent cell division, inducing apoptosis in cancer cells.","indications":["Metastatic breast cancer","Non-small cell lung cancer","Pancreatic cancer","Ovarian cancer"],"catalyst":""},{"name":"Pumitamig","genericName":"Pumitamig","slug":"pumitamig","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-12-14","type":"regulatory","headline":"BioNTech Receives FDA Approval for COVID-19 Vaccine","summary":"BioNTech's COVID-19 vaccine, Comirnaty, has received FDA approval for emergency use in the US.","drugName":"Comirnaty","sentiment":"positive"},{"date":"2023-11-02","type":"deal","headline":"BioNTech and Pfizer Announce Collaboration on mRNA-Based Cancer Therapies","summary":"BioNTech and Pfizer have announced a collaboration to develop and commercialize mRNA-based cancer therapies.","drugName":"","sentiment":"positive"},{"date":"2023-08-04","type":"earnings","headline":"BioNTech Reports Second-Quarter 2023 Earnings","summary":"BioNTech has reported its second-quarter 2023 earnings, with revenue of $4.3 billion.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-04-02","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-24","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNR1RSbmdma2Z6NGJydEc0cFUzejZiX3lGZzhWZmNuNGNJM2cwQlJpSXlzQlAzejZmVnFSTzRla3NoVkMtN04zQ0NjUk1uTHlfTFJSMG8zbkRTQjY2eVNCUXgwRXZIUVFpOGxHZjhXMFJHaXNEMk1ZeTAtTF8wcmg2TlQ3czVNdDRjRnRUbXdoTmlYRmVBODM0aVZ6aE1SV21nSTBaRTNpVXFSQms?oc=5","date":"2026-03-16","type":"pipeline","source":"The Motley Fool","summary":"Best Vaccine Stocks of 2026: Are They Right for Your Portfolio? - The Motley Fool","headline":"Best Vaccine Stocks of 2026: Are They Right for Your Portfolio?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQRnppRzYzTGx1QzdCQ1pzVXZOaW05X3RXN1lEZER6aDVWQkhWendTa3ZaNmdLWFV1RUVGNFg1OUFjSmpuZl9Mc0RadVVVRnpvOWlVcmdMLUcxcVlCalEtNXJNLWFpWEpoLVc5Tlo2RWZjZlBrS1c2bDVJLU52a1pzXzJ0emJWbHhLSDhBM0p2R080b19BR1VnaklB?oc=5","date":"2026-03-10","type":"pipeline","source":"Fierce Pharma","summary":"Leerink questions whether BioNTech can thrive without their 'founders' insight' as stock drops - Fierce Pharma","headline":"Leerink questions whether BioNTech can thrive without their 'founders' insight' as stock drops","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQNmxrSWE0ZUljbGlDU3cta3MycnpsZTRfUURfdWlWaktDQ2d0YnZ1eVdNQXd0U2kzMUo5Q2pQMkxETU9FLXhIOXJVdWNWdkdia2JuU24wWTc2MnJsOHA0c253SmJWbXVrcENKVkFLSjV5WHZ3MGVZTFZTd0cyQWZjSFc0SFR6OWFjV24xQVBzLUI4ZW1pWUN1emM2dG4?oc=5","date":"2026-03-10","type":"pipeline","source":"Fierce Biotech","summary":"BioNTech's CEO, CMO prep departure to set up next-gen mRNA company - Fierce Biotech","headline":"BioNTech's CEO, CMO prep departure to set up next-gen mRNA company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxORWx1NTliZE5Gbm9JQTc5eWNBTDdjUWI3UEZtenJzM3g4aHJfVDF3cEtQNkdFQUpXQ2pWNW9qTkkxVFVjaVJPS0ZkbkptSmFrT2ZDQlktRE5UZG8ycGRpSl9nZ1JtY19fY1BTeDBGbXliS1RWVVdfUVNFaXpLVjdrT2s2dW5JNi1ZcjVSQ3lfMnVnekQzWE03dHZLbW9uQ1hX?oc=5","date":"2026-03-10","type":"pipeline","source":"CNBC","summary":"Stocks making the biggest moves midday: Rivian, Hims & Hers, BioNTech, Vertex Pharmaceuticals & more - CNBC","headline":"Stocks making the biggest moves midday: Rivian, Hims & Hers, BioNTech, Vertex Pharmaceuticals & more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOZldxZmw5VEdycU5KYmZweWFYSFR0cWhxOUtNUHRnQUExVTlsX3JOQWg3ZmFVN21pVV9Da21TdER3M2o1SnVIdTc1azV6Mm1wUlVFenFzUzVMZHk4Z0ZXbjlIaFc0UHA5Mlk5UU9LSDVvYXVtYnU3SUlJVjZjM3U3VjRn?oc=5","date":"2026-03-10","type":"pipeline","source":"TradingKey","summary":"Vertex Pharmaceuticals Inc Stock (VRTX) Moved Up by 8.03% on Mar 10: What Signal Does It Send? - TradingKey","headline":"Vertex Pharmaceuticals Inc Stock (VRTX) Moved Up by 8.03% on Mar 10: What Signal Does It Send?","sentiment":"neutral"},{"date":"2026-03-10","type":"earnings","source":"SEC EDGAR","summary":"20-F filed with SEC: 20-F","headline":"Annual Report (20-F) Filed","sentiment":"neutral"},{"date":"2026-03-10","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-10","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQUzJDQTRnQ2pOU0JoUUJRT2YxYm9Qc3hIaFY4WktwR09HeDFLaVRCQ0dRRzF4RHJ1RnN3cTFVUFUyVzVjVFJjZmpuS3VCbTlpQ1RTQi1OcnhPWFZ1ZUJWTHpDN1hwbW51UGlBdUlFU3NrYzdXSWRob1Y0Q3F1QUs3c3dNcl9sNU16amtjT2lB?oc=5","date":"2026-02-05","type":"pipeline","source":"The Motley Fool","summary":"Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool","headline":"Best Biotech Stocks of 2026 and How to Invest in Them","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1iTEw4UmJiSHg0bFJFSmg4SkRtZ3VxczVsUTQxWHJsMmt5aUplUTNyaDVuLTdmbENFN0JxWnlCQkdPUG42UTdqcjBVRVo1SUEydElvRFN6Wjd4a2s1d1lzUjdzSGNIemlsU0FtX2d4Z0RUeGxB?oc=5","date":"2025-12-18","type":"pipeline","source":"CureVac","summary":"CureVac is now part of the BioNTech Group - CureVac","headline":"CureVac is now part of the BioNTech Group","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5GV2tSdkx6b2hma1FNalhjNC1CZ2c3SzhjLVV6VkhIRjRNS2RKTFFQamFhOXdJTmtVQnlCY0F1clVuQmoxV055Y01XWDNSREJqUExYVUlCWkhrcjZZdDRJ?oc=5","date":"2025-11-27","type":"pipeline","source":"Intellectia AI","summary":"5 Best AI Biotech Stocks to Watch in 2026: The Future of Medicine - Intellectia AI","headline":"5 Best AI Biotech Stocks to Watch in 2026: The Future of Medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQa05FSVl1VzgxRk5qSVlmV2NmLUNFclh1ZHowR1hYR1J3dUpqcmhJZjRxcldOU2ZuTk1vQlZ1X0NSV3pVMVgyU3pQSm50cm1ER0R0SlZpbVZndVpMdzQwWGV4aVE0TEpITVpJQWNtQmx0cXdtTDFaenN6QUJOOTZLaU9tczZCSmt5VXFoZEZmTTlsRlZaSG9VMzRoQW9nTlBvdTk0RFRKMHJWN3poYlNoWnRzaFUtQTZ3NjQ0TDVmTUd0ZVhRUWZlZGh2cTRBcXI0UVAxTlNSaEkyU19L?oc=5","date":"2025-11-13","type":"deal","source":"reuters.com","summary":"Pfizer slashes stake in COVID vaccine partner BioNTech - reuters.com","headline":"Pfizer slashes stake in COVID vaccine partner BioNTech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxOMDRoQjMzVEYyZjF5bnRlWUxZSkh6RUlUYlI2Yk1LazBFWFQwT2NYdWdKVldPUzJzaDluMDVFcEVNX0Z2WHZwMzlhZUFQeEFnZzlWamR5STk4Wmk5TFozTWxYM3hJNXMzTFJHQ3Zkc19FY2tNQnY1RnlibUdGdmNZX1I4bmg4ZnhzdVZwbW1ZcmtfYXBoWG1Lb29RVk9PaDdsaXRxVVBRS2Nkb1BhSVdBdGdfVTQ4VmlkQVZMU3F5Mm5LNkxzaFdpa0RZbDZwY2pkOVI3dVBiUS14VFRnVGs1QjE1d2lDeDljc0kzQ1FyS2FHV2VBN3BxLTlPeEt0LU0xdWRNcXhjQUlRYUN2Y3pOUnUwNG9GeVh5d3U5Tlpfb2piUQ?oc=5","date":"2025-11-13","type":"deal","source":"Stocktwits","summary":"BioNTech Says Collaboration With Pfizer Going Strong After Report Indicated US Pharma Giant Considering Stake Sale In The German Company - Stocktwits","headline":"BioNTech Says Collaboration With Pfizer Going Strong After Report Indicated US Pharma Giant Considering Stake Sale In Th","sentiment":"neutral"}],"patents":[{"drugName":"Ritonavir","drugSlug":"ritonavir","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":21,"phaseCounts":{"marketed":5,"phase_3":6,"phase_1":3,"phase_2":7},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Moderna Therapeutics","Pfizer","Merck & Co."],"therapeuticFocus":["Oncology","Infectious Diseases"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":91.34,"previousClose":89.62,"fiftyTwoWeekHigh":124,"fiftyTwoWeekLow":79.52,"fiftyTwoWeekRange":"79.52 - 124.0","fiftyDayAverage":101.49,"twoHundredDayAverage":103.37,"beta":1.59,"enterpriseValue":8032983552,"forwardPE":-21.6,"priceToBook":1.03,"priceToSales":8.05,"enterpriseToRevenue":2.8,"enterpriseToEbitda":-7.15,"pegRatio":0,"ebitda":-1124099968,"ebitdaMargin":-39.2,"freeCashflow":-1098362496,"operatingCashflow":456000000,"totalDebt":267400000,"debtToEquity":1.4,"currentRatio":7.54,"returnOnAssets":-3.6,"returnOnEquity":-5.9,"analystRating":"1.6 - Buy","recommendationKey":"buy","numberOfAnalysts":18,"targetMeanPrice":131.86,"targetHighPrice":173.32,"targetLowPrice":76.77,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":1654128000,"insiderHeldPercent":57.4,"institutionHeldPercent":20.6,"sharesOutstanding":252884261,"floatShares":96643442,"sharesShort":3537489,"shortRatio":2.29,"shortPercentOfFloat":1.4,"epsTrailing":-5.41,"epsForward":-4.23,"revenuePerShare":11.87,"bookValue":88.53,"officers":[{"age":60,"name":"Dr. Ugur  Sahin M.D.","title":"Co-Founder, CEO & Chair of the Management Board"},{"age":58,"name":"Dr. Ozlem  Tureci M.D.","title":"Co-Founder, Chief Medical Officer & Member of Management Board"},{"age":51,"name":"Mr. Ramon  Zapata-Gomez","title":"CFO & Member of Management Board"},{"age":52,"name":"Dr. Sierk  Pötting Ph.D.","title":"MD, COO & Member of Management Board"},{"age":50,"name":"Dr. James Timothy Patrick Ryan Ph.D.","title":"Chief Legal & Business Officer and Member of the Management Board"},{"age":45,"name":"Ms. Annemarie  Hanekamp","title":"Chief Commercial Officer & Member of Management Board"},{"age":48,"name":"Ms. Kylie  Jimenez","title":"Chief People Officer & Member of Management Board"},{"age":null,"name":"Ms. Lisa  Birringer","title":"Senior Vice President of Global Financial Reporting & Accounting"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.biontech.de","phone":"49 6131 9084"}}